ENXTAM:PHARMBiotechs
How Investors Are Reacting To Pharming Group (ENXTAM:PHARM) Beating Guidance And Easing Market Share Fears
Pharming Group recently reported preliminary 2025 revenues that were around 27% higher than the prior year, slightly above its own guidance and easing fears about market share erosion to a rival therapy.
The company also highlighted a strong outlook for Joenja/leniolisib and upcoming clinical trial read-outs, suggesting its rare disease portfolio could be an increasingly important growth engine.
Next, we’ll examine how this better‑than‑expected revenue performance and confidence around...